Literature DB >> 12161606

A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer.

P O Chappuis, J Goffin, N Wong, C Perret, P Ghadirian, P N Tonin, W D Foulkes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12161606      PMCID： PMC1735193          DOI： 10.1136/jmg.39.8.608

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  39 in total

Review 1.  Fine tuning chemotherapy to match BRCA1 status.

Authors:  Melissa Price; Alvaro N A Monteiro
Journal:  Biochem Pharmacol       Date:  2010-05-25       Impact factor: 5.858

Review 2.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

3.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Authors:  Helen Davies; Dominik Glodzik; Sandro Morganella; Lucy R Yates; Johan Staaf; Xueqing Zou; Manasa Ramakrishna; Sancha Martin; Sandrine Boyault; Anieta M Sieuwerts; Peter T Simpson; Tari A King; Keiran Raine; Jorunn E Eyfjord; Gu Kong; Åke Borg; Ewan Birney; Hendrik G Stunnenberg; Marc J van de Vijver; Anne-Lise Børresen-Dale; John W M Martens; Paul N Span; Sunil R Lakhani; Anne Vincent-Salomon; Christos Sotiriou; Andrew Tutt; Alastair M Thompson; Steven Van Laere; Andrea L Richardson; Alain Viari; Peter J Campbell; Michael R Stratton; Serena Nik-Zainal
Journal:  Nat Med       Date:  2017-03-13       Impact factor: 53.440

Review 4.  BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis.

Authors:  William D Foulkes
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

5.  In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.

Authors:  G Metro; Z Zheng; A Fabi; M Schell; B Antoniani; M Mottolese; A N Monteiro; P Vici; S Lara Rivera; D Boulware; F Cognetti; G Bepler
Journal:  Cancer Invest       Date:  2010-02       Impact factor: 2.176

Review 6.  Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook.

Authors:  Zeina Nahleh
Journal:  Med Oncol       Date:  2009-06-10       Impact factor: 3.064

7.  The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.

Authors:  Mireia Margeli; Beatriz Cirauqui; Eva Castella; Gustavo Tapia; Carlota Costa; Ana Gimenez-Capitan; Agusti Barnadas; Maria Sanchez Ronco; Susana Benlloch; Miquel Taron; Rafael Rosell
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

8.  Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.

Authors:  Laura Cortesi; Cristina Masini; Claudia Cirilli; Veronica Medici; Isabella Marchi; Giovanna Cavazzini; Giuseppe Pasini; Daniela Turchetti; Massimo Federico
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

Review 9.  BRCA1 functions as a breast stem cell regulator.

Authors:  W D Foulkes
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

Review 10.  Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

Authors:  Catherine Oakman; Silvia Bessi; Elena Zafarana; Francesca Galardi; Laura Biganzoli; Angelo Di Leo
Journal:  Breast Cancer Res       Date:  2009-04-03       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.